

Table 3.1
Verified Outcomes (Annualized Percentages) by Age at Enrollment for MRC Super Cohort Participants¹

Data as of: March 31, 2018; Events through March 31, 2018

Outcomes	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Number randomized	44174	6788	9352	19418	8616
Mean follow-up (months)	173.0	183.7	184.6	174.2	149.5
Cardiovascular					
CHD ²	3399 (0.53%)	228 (0.22%)	424 (0.29%)	1596 (0.57%)	1151 (1.07%)
CHD death ³	1444 (0.23%)	55 (0.05%)	132 (0.09%)	619 (0.22%)	638 (0.59%)
Clinical MI	2355 (0.37%)	182 (0.18%)	326 (0.23%)	1149 (0.41%)	698 (0.65%)
Angina ⁴	1625 (0.47%)	114 (0.20%)	226 (0.30%)	785 (0.52%)	500 (0.76%)
CABG/PTCA	2958 (0.46%)	235 (0.23%)	485 (0.34%)	1517 (0.54%)	721 (0.67%)
Carotid artery disease	514 (0.08%)	23 (0.02%)	80 (0.06%)	282 (0.10%)	129 (0.12%)
Congestive heart failure, WHI ⁴	1246 (0.36%)	84 (0.15%)	145 (0.19%)	531 (0.35%)	486 (0.74%)
Heart failure, UNC ⁵	2781 (0.44%)	174 (0.17%)	292 (0.20%)	1313 (0.47%)	1002 (0.95%)
Stroke	2685 (0.42%)	172 (0.17%)	320 (0.22%)	1296 (0.46%)	897 (0.84%)
PVD	656 (0.10%)	42 (0.04%)	97 (0.07%)	341 (0.12%)	176 (0.16%)
DVT	1081 (0.17%)	95 (0.09%)	186 (0.13%)	515 (0.18%)	285 (0.27%)
Pulmonary embolism	861 (0.14%)	83 (0.08%)	149 (0.10%)	420 (0.15%)	209 (0.19%)
DVT/PE	1550 (0.24%)	132 (0.13%)	264 (0.18%)	757 (0.27%)	397 (0.37%)
Coronary disease ⁶	7233 (1.14%)	540 (0.52%)	1000 (0.70%)	3428 (1.22%)	2265 (2.11%)
Aortic aneurysm ⁷	57 (0.04%)	4 (0.02%)	7 (0.02%)	36 (0.06%)	10 (0.06%)
Valvular heart disease ⁷	394 (0.29%)	25 (0.10%)	53 (0.15%)	218 (0.35%)	98 (0.59%)
Total cardiovascular disease⁸	9985 (1.57%)	721 (0.69%)	1379 (0.96%)	4745 (1.68%)	3140 (2.92%)
Cancer					
Breast cancer	2867 (0.45%)	426 (0.41%)	650 (0.45%)	1304 (0.46%)	487 (0.45%)
Invasive breast cancer	2349 (0.37%)	329 (0.32%)	532 (0.37%)	1060 (0.38%)	428 (0.40%)
Non-invasive breast cancer	572 (0.09%)	103 (0.10%)	128 (0.09%)	274 (0.10%)	67 (0.06%)
Ovarian cancer	266 (0.04%)	24 (0.02%)	54 (0.04%)	137 (0.05%)	51 (0.05%)
Endometrial cancer ⁹	320 (0.09%)	50 (0.09%)	85 (0.10%)	136 (0.08%)	49 (0.08%)
Colorectal cancer	909 (0.14%)	82 (0.08%)	146 (0.10%)	441 (0.16%)	240 (0.22%)
Other cancer ¹⁰	3984 (0.63%)	372 (0.36%)	705 (0.49%)	1956 (0.69%)	951 (0.89%)
Total cancer	7772 (1.22%)	896 (0.86%)	1543 (1.07%)	3681 (1.31%)	1652 (1.54%)
Fractures					
Hip fracture	1454 (0.23%)	46 (0.04%)	117 (0.08%)	639 (0.23%)	652 (0.61%)
Deaths					
Cardiovascular deaths	3146 (0.49%)	124 (0.12%)	284 (0.20%)	1339 (0.47%)	1399 (1.30%)
Cancer deaths	2922 (0.46%)	224 (0.22%)	449 (0.31%)	1431 (0.51%)	818 (0.76%)
Other known cause	2855 (0.45%)	143 (0.14%)	289 (0.20%)	1292 (0.46%)	1131 (1.05%)
Unknown cause	82 (0.01%)	9 (0.01%)	12 (0.01%)	39 (0.01%)	22 (0.02%)
Not yet adjudicated	403 (0.06%)	21 (0.02%)	44 (0.03%)	233 (0.08%)	105 (0.10%)
Total death	9408 (1.48%)	521 (0.50%)	1078 (0.75%)	4334 (1.54%)	3475 (3.24%)
Death plus post-WHI deaths	14888 (1.86%)	795 (0.59%)	1650 (0.91%)	6720 (1.92%)	5723 (4.28%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2020.

³ "CHD death" includes definite and possible CHD death.

⁴ Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2020. Reported statistics represent experience during the original program.

⁵ Definite or possible decompensated heart failure adjudicated by UNC.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure are not collected in the WHI Extension Studies 2005-2020.

⁷ Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2020.

⁸ Total CVD does not include aortic aneurysm or valvular heart disease.

⁹ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

¹⁰ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.